2012 and beyond: potential for the start of a second pre-antibiotic era?
2012 and beyond: potential for the start of a second pre-antibiotic era?
复制标题
DOI：
10.1093/jac/dks213
复制
发表时间：
2012-09-01
影响因子：
5.2
通讯作者：
Appelbaum, Peter C.
中科院分区：
文献类型：
--
作者：
Appelbaum, Peter C.
在过去的十年中，与新抗菌药物的开发相反的情况令人震惊地融合在一起，并且正在开发的极少数新药中的大多数都存在微生物学、毒性或药代动力学和药效学问题。大多数大型制药公司已经放弃了抗生素产品组合，而初创公司填补这一空白的承诺尚未兑现。该领域的剩余发展正受到官僚法规、审批问题、缺乏专业知识以及普遍缺乏对情况严重性的了解的抑制。特别是在儿科领域，在可预见的将来没有任何新抗菌药物的迹象。等待倡议和审议可能需要太长时间，而积极而深思熟虑地努力教育公众，进而施加必要的压力，似乎是迅速扭转这一最危险局势的唯一途径。
The past decade has seen an alarming confluence of circumstances antithetical to development of new antibacterials, and most of the very few new drugs under development have problems with their microbiology, toxicity, or pharmacokinetics and pharmacodynamics. Most large pharmaceutical companies have divested themselves of their antibiotic portfolios, and the promise that start-up companies would fill the niche has not been fulfilled. What is left of the field is being stifled by bureaucratic regulations, problems with approval, lack of expertise and a general lack of understanding of how serious the situation is. In paediatrics, in particular, there is no sign of any new antibacterial in the foreseeable future. Waiting for initiatives and deliberations will probably take too long, and a vigorous and deliberate effort to educate the publicwho in their turn can apply the needed pressureseems to be the only way of achieving a rapid turnaround of this most dangerous situation.